COCRYSTAL PHARMA, INC. Increase (Decrease) in Income Taxes Receivable
COCRYSTAL PHARMA, INC. (COCP) reported Increase (Decrease) in Income Taxes Receivable of -$7.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2026-08-13
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for the quarter ending 2026-06-30 was $8.00K, a 95.96% decline year-over-year.
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for the quarter ending 2026-03-31 was -$15.00K, a 106.55% decline year-over-year.
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for the quarter ending 2025-12-31 was $193.00K, a 65.72% decline year-over-year.
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for the quarter ending 2025-09-30 was -$1.13M.
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for fiscal 2025 was -$509.00K, a 256.62% decline from fiscal 2024.
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for fiscal 2024 was $325.00K, a 86.78% increase from fiscal 2023.
- COCRYSTAL PHARMA, INC. increase (decrease) in income taxes receivable for fiscal 2023 was $174.00K.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$7.00K 10-Q · filed 2026-08-13 | $186.00K derived: sum of 3 quarters · filed 2026-08-13 | -$943.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$15.00K 10-Q · filed 2026-05-15 | $178.00K derived: sum of 2 quarters · filed 2026-05-15 | -$951.00K derived: sum of 3 quarters · filed 2026-05-15 | -$753.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$936.00K derived: sum of 2 quarters · filed 2026-03-31 | -$738.00K derived: sum of 3 quarters · filed 2026-08-13 | -$509.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$931.00K derived: sum of 2 quarters · filed 2026-08-13 | -$702.00K 10-Q · filed 2025-11-14 | -$139.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $427.00K 10-Q · filed 2026-08-13 | $990.00K derived: sum of 3 quarters · filed 2026-08-13 | $565.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $229.00K 10-Q · filed 2026-05-15 | $792.00K derived: sum of 2 quarters · filed 2026-05-15 | $367.00K derived: sum of 3 quarters · filed 2026-05-15 | $441.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $138.00K derived: sum of 2 quarters · filed 2026-03-31 | $212.00K derived: sum of 3 quarters · filed 2026-03-31 | $325.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$425.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$351.00K derived: sum of 2 quarters · filed 2025-11-14 | -$238.00K 10-Q · filed 2025-11-14 | $102.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $187.00K 10-Q · filed 2025-08-14 | $527.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $113.00K 10-Q · filed 2025-05-15 | $453.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $174.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$166.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |